World Journal of Emergency Medicine, 2024, 15(3): 197-203 doi: 10.5847/wjem.j.1920-8642.2024.047

Original Articles

Glucose metabolic reprogramming-related parameters for the prediction of 28-day neurological prognosis and all-cause mortality in patients after cardiac arrest: a prospective single-center observational study

Subi Abudurexiti1, Shihai Xu2, Zhangping Sun3, Yi Jiang4, Ping Gong,2

1Department of Emergency Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

2Department of Emergency Medicine, Shenzhen People's Hospital (the Second Clinical Medical College, Jinan University, the First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China

3Department of Emergency Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

4Department of Emergency Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China

Corresponding authors: Ping Gong, Email:gongp828@sina.cn

Received: 2023-11-12   Accepted: 2024-03-6  

Abstract

BACKGROUND: We aimed to observe the dynamic changes in glucose metabolic reprogramming-related parameters and their ability to predict neurological prognosis and all-cause mortality in cardiac arrest patients after the restoration of spontaneous circulation (ROSC).
METHODS: Adult cardiac arrest patients after ROSC who were admitted to the emergency or cardiac intensive care unit of the First Affiliated Hospital of Dalian Medical University from August 1, 2017, to May 30, 2021, were enrolled. According to 28-day survival, the patients were divided into a non-survival group (n=82) and a survival group (n=38). Healthy adult volunteers (n=40) of similar ages and sexes were selected as controls. The serum levels of glucose metabolic reprogramming-related parameters (lactate dehydrogenase [LDH], lactate and pyruvate), neuron-specific enolase (NSE) and interleukin 6 (IL-6) were measured on days 1, 3, and 7 after ROSC. The Acute Physiology and Chronic Health Evaluation II (APACHE II) score and Sequential Organ Failure Assessment (SOFA) score were calculated. The Cerebral Performance Category (CPC) score was recorded on day 28 after ROSC.
RESULTS: Following ROSC, the serum LDH (607.0 U/L vs. 286.5 U/L), lactate (5.0 mmol/L vs. 2.0 mmol/L), pyruvate (178.0 μmol/L vs. 70.9 μmol/L), and lactate/pyruvate ratio (34.1 vs. 22.1) significantly increased and were higher in the non-survivors than in the survivors on admission (all P<0.05). Moreover, the serum LDH, pyruvate, IL-6, APACHE II score, and SOFA score on days 1, 3 and 7 after ROSC were significantly associated with 28-day poor neurological prognosis and 28-day all-cause mortality (all P<0.05). The serum LDH concentration on day 1 after ROSC had an area under the receiver operating characteristic curve (AUC) of 0.904 [95% confidence interval [95% CI]: 0.851-0.957]) with 96.8% specificity for predicting 28-day neurological prognosis and an AUC of 0.950 (95% CI: 0.911-0.989) with 94.7% specificity for predicting 28-day all-cause mortality, which was the highest among the glucose metabolic reprogramming-related parameters tested.
CONCLUSION: Serum parameters related to glucose metabolic reprogramming were significantly increased after ROSC. Increased serum LDH and pyruvate levels, and lactate/pyruvate ratio may be associated with 28-day poor neurological prognosis and all-cause mortality after ROSC, and the predictive efficacy of LDH during the first week was superior to others.

Keywords: Glucose metabolic reprogramming; Lactate dehydrogenase; Cardiac arrest; Prognosis

PDF (320KB) Metadata Metrics Related articles Export EndNote| Ris| Bibtex  Favorite

Cite this article

Subi Abudurexiti, Shihai Xu, Zhangping Sun, Yi Jiang, Ping Gong. Glucose metabolic reprogramming-related parameters for the prediction of 28-day neurological prognosis and all-cause mortality in patients after cardiac arrest: a prospective single-center observational study. World Journal of Emergency Medicine, 2024, 15(3): 197-203 doi:10.5847/wjem.j.1920-8642.2024.047

INTRODUCTION

Cardiac arrest (CA) is associated with high mortality and morbidity.[1,2] CA results in a sharp decrease in intracellular adenosine triphosphate (ATP) levels, which directly causes dysfunction of vital organs (e.g., the brain and the heart). After the return of spontaneous circulation (ROSC), glucose metabolism, including glycolysis and the tricarboxylic acid cycle, may be reprogrammed despite the recovery of oxygen delivery, which has been involved in ischemia/reperfusion (I/R) injury.[3]

Glycolysis and tricarboxylic acid cycle are the two primary pathways that produce ATP. During CA, ATP is produced by anaerobic glycolysis. Through glycolysis, glucose is metabolized by phosphofructokinase into pyruvate. To further metabolize pyruvate, one of two routes is followed. The first route is the conversion of pyruvate into acetyl coenzyme A by pyruvate dehydrogenase under aerobic conditions. Acetyl coenzyme A subsequently enters the energy-generating tricarboxylic acid (Krebs) cycle. In addition, pyruvate can also be converted to lactate under anaerobic conditions via lactate dehydrogenase (LDH) in the cytosol. In this reaction, LDH catalyzes both processes, resulting in an approximately 10-to-1 lactate-pyruvate ratio.[4] During tissue hypoxia, the tricarboxylic acid cycle produces lactate because pyruvate cannot be metabolized. However, lactate production can also occur independent of tissue hypoxia. As a result, cellular glucose metabolism switches rapidly from oxidative phosphorylation to glycolysis (aerobic glycolysis), which is referred to as glucose metabolic reprogramming (i.e., the Warburg effect). First discovered in tumor cells, the Warburg effect refers to the process by which cells generate energy through glycolysis rather than oxidative phosphorylation despite the presence of oxygen.[5] Cytosolic ATP production is approximately 100 times faster than that of mitochondria.[6] Therefore, reprogramming glucose metabolism from oxidative to more anaerobic ATP production may be an important mechanism to keep cells alive for as long as possible.

Glucose metabolic reprogramming has been described in post-ischemic reperfusion injury, as evidenced by decreased glucose oxidation and lactate uptake.[7] However, the association between changes in glucose metabolic reprogramming and patient outcomes after ROSC remains unclear. Here, we hypothesized that glucose metabolic reprogramming-related parameters could predict patient outcomes after ROSC.

METHODS

Enrolled participants

Between August 1, 2017, and May 30, 2021, resuscitated CA patients were prospectively enrolled in the emergency intensive care unit (ICU) and cardiac ICU of the First Affiliated Hospital of Dalian Medical University. All enrolled patients received post-ROSC treatments in accordance with the 2015 and 2020 Advanced Life Support (ALS) recommendation.[8,9] Based on the survival status on day 28 after ROSC, two groups (survivors and non-survivors) were established. Healthy adult volunteers of similar sex and age were recruited as controls. We complied with the World Medical Association’s Declaration of Helsinki (2013 edition).[10] Study approval was obtained from the Medical Ethics Committee of the First Affiliated Hospital of Dalian Medical University (PJ-KS-KY-2021-214), and written informed consent was obtained from all subjects or their legal guardians.

Inclusion and exclusion criteria

The study included patients aged 18 years and older who were resuscitated successfully after out-of-hospital or in-hospital CA. Patients who had skeletal muscle injury, progressive muscular atrophy, pulmonary infarction, hematological diseases, acute or chronic liver diseases, malignancies, or CA caused by trauma or who were pregnant were excluded.

Data collection

The primary outcomes were 28-day poor neurological prognosis and all-cause mortality. Clinical data, including demographic characteristics, CA and CPR, comorbid conditions, length of ICU stay, laboratory findings, and outcomes, were collected. APACHE II and SOFA scores were calculated on days 1, 3 and 7 after ROSC. The Cerebral Performance Category (CPC) score was assessed on day 28 after ROSC, and 3-5 points was defined as a poor neurological outcome, while 1-2 points was defined as a good neurological outcome.

Measurement of serum biomarkers

Venous blood was drawn from patients on days 1, 3 and 7 after ROSC and from healthy volunteers on the enrolled day. Blood samples were centrifuged at 1,000 × g for 15 min at 4 °C and then stored at -80 °C. Serum neuron-specific enolase (NSE) (Roche Diagnostics GmbH, Germany), interleukin (IL)-6 (Siemens Healthcare Diagnostics Ltd., Germany), LDH (Fujifilm Wako Pure Chemical Co., Japan), and pyruvate (Elabscience, China) were detected by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions. Lactate (VITROS Chemistry Products LAC Slides, Ortho-Clinical Diagnostics, Inc., USA) was detected by colorimetric method.

Statistical analyses

The data were analyzed using SPSS v24.0 (IBM, USA) and Med Calc v19.1 (MedCalc Software Ltd., Belgium). Based on the preliminary estimates of the corresponding means and standard deviations,[11] 60 patients were included and divided into survivor (n=30) or non-survivor groups (n=30), and 30 healthy volunteers were necessary to provide 90% power with a two-sided α = 0.05 to detect a 0.5-5.0 difference in the three time points among the three groups for the change in LDH (a main variable in the present study).Numbers and percentages are used to represent categorical data, while medians with interquartile ranges are used for continuous data. Pearson’s Chi-square test or Fisher’s exact test was applied (as appropriate) to compare the indices of demographic characteristics. Repeated-measure analysis of variance (ANOVA) or Kruskal-Wallis one-way ANOVA was used to evaluate changes in variables at different time points among the three groups, which were followed by the Bonferroni test for multiple comparisons or the Mann-Whitney U test for two-group comparisons. Multivariate logistical regression analysis was conducted to determine the factors associated with 28-day poor neurological prognosis and all-cause mortality. The receiver operating characteristic (ROC) curve analysis was performed to determine the value of the selected parameters for predicting 28-day poor neurological prognosis and all-cause mortality. According to DeLong’s test, areas under the ROC curves (AUCs) were compared. According to the optimal thresholds determined by analyzing ROC curves, prognostic parameters (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], Youden index, positive likelihood ratio [LR+] and negative likelihood ratio [LR−]) were also derived. P<0.05 was considered to indicate statistical significance.

RESULTS

Baseline characteristics

A total of 215 patients and 40 healthy volunteers were enrolled (supplementary Figure 1). Ninety-five patients were excluded, and 120 patients were ultimately eligible. Sex and age did not differ significantly among healthy volunteers (n=40, Table 1), survivors (n=38) and non-survivors (n=82) or between patients with good and poor neurological outcomes (Table 2). There were no significant differences in comorbidities, location of arrest, causes of CA, or laboratory findings between non-survivors and survivors (Table 1) or between patients with good and poor neurological outcomes (Table 2). However, both non-survivors and patients with poor neurological outcomes had less witnessed CA and bystander CPR and longer CPR time, higher APACHE II score and SOFA score (all P<0.05, Tables 1 and 2). Non-survivors had less ventricular fibrillation (VF), a shorter length of ICU stay, and more asystole, pulseless activity and unknown initial heart rhythm (all P<0.05, Table 1). A total of 60.5% (23/38) of the survivors had a 28-day CPC of 1-2 points.

Table 1.   Baseline characteristics of the enrolled participants on ICU admission

ParametersHealthy volunteers
(n=40)
Survivors
(n=38)
Non-survivors
(n=82)
P-valuea
Age, years, median (IQR)58.9 (39.8-72.0)64.5 (51.3-77.8)73.0 (60.0-82.2)0.608
Male, n (%)21 (52.5)24 (63.2)47 (57.3)0.690
Comorbidities, n (%)
Diabetes10 (26.3)31 (37.8)0.301
Hypertension16 (42.1)39 (47.6)0.694
Coronary heart disease9 (23.7)18 (21.9)0.210
Cerebrovascular disease5 (13.2)15 (18.3)0.603
Chronic pulmonary disease4 (10.5)4 (4.9)0.261
Chronic kidney disease6 (7.3)
CA causes, n (%)
Cardiac24 (63.2)42 (51.2)0.243
Respiratory2 (5.3)9 (11.0)0.499
Septic5 (13.2)13 (15.9)0.790
Cerebral3 (7.9)13 (15.9)0.386
Others4 (10.5)5 (6.1)0.462
Out-of-hospital CA, n (%)10 (26.3)34 (41.5)0.154
Witnessed CA, n (%)33 (86.8)55 (67.1)0.027
Bystander CPR, n (%)34 (89.5)59 (72.0)0.036
Initial cardiac rhythm, n (%)
VT1 (2.6)4 (4.9)0.492
VF10 (26.3)10 (12.2)0.047
Asystole and pulseless activity16 (42.1)17 (20.7)0.027
Unknown11 (28.9)51 (62.2)0.001
CPR time, min, median (IQR)10.0 (5.0-25.0)15.0 (6.5 -28.5)0.016
Length of ICU stay, d, median (IQR)8 (5-12)5 (2-11)0.003
Laboratory findings, median (IQR)
WBC, ×109/L6.82 (5.45-8.49)12.40 (8.74-18.60)14.88 (10.42-20.08)0.201
Neutrophil ratio, %57.3 (50.2-63.4)84.3 (76.6-90.2)87.7 (82.9-91.3)0.084
PCT, ng/mL0.15 (0.01-0.33)1.82 (0.91-5.67)4.59 (0.83-11.00)0.159
Creatinine, μmol/L64.5 (57.2-79.2)103.0 (85.5-178.0)137.0 (91.8-231.3)0.183
High sensitivity troponin I, μg/L0.01 (0.00-0.03)0.22 (0.09-3.93)0.94 (0.21-8.57)0.112
BNP, pg/mL30.8 (22.3-45.9)371.0 (119.7-1120.0)787.8 (233.1-1988.5)0.070
PO2/FiO2, mmHg460.0 (410.8-482.0)320.0 (240.5-398.3)229.0 (157.0-335.3)0.259
Blood glucose, μmol/L5.2 (4.7-5.7)8.6 (4.7-9.7)8.7 (6.0-13.2)0.342
APACHE II score, median (IQR)14.0 (9.8-20.0)23.0 (19.0-26.0)<0.01
SOFA score, median (IQR)5.5 (4.0-7.8)12.0 (10.0-14.5)<0.01

IQR: interquartile range; ICU: intensive care unit; CA: cardiac arrest; CPR: cardiopulmonary resuscitation; VF: ventricular fibrillation; VT: ventricular tachycardia; WBC: white blood cell; PCT: procalcitonin; BNP: brain natriuretic peptide; PO2/FiO2: partial pressure of oxygen/ fraction of inspiration oxygen; APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; a: P values for the comparison of survivor and non-survivor groups.

New window| CSV


Table 2.   Baseline characteristics of the enrolled participants on ICU admission according to neurological outcome

ParametersHealthy volunteers
(n=40)
Good neurological outcome (n=23)Poor neurological outcome (n=97)P-valuea
Age, years, median (IQR)58.9 (39.8-72.0)66.0 (55.0-80.0)75.0 (54.0-82.3)0.141
Male, n (%)21 (52.5)16 (69.6)55 (56.7)0.584
Comorbidities, n (%)
Diabetes9 (39.1)33 (34.0)0.841
Hypertension10 (43.5)46 (47.4)0.871
Coronary heart disease8 (34.8)34 (35.1)0.681
Cerebrovascular disease4 (17.4)17 (17.5)0.523
Chronic pulmonary disease3 (13.0)7 (7.2)0.379
Chronic kidney disease6 (6.2)0.114
CA causes, n (%)
Cardiac14 (60.8)48 (49.4)0.320
Respiratory4 (17.4)9 (9.2)0.621
Septic3 (13.0)9 (9.2)0.606
Cerebral1 (4.3)14 (14.4)0.224
Others1 (4.3)17 (19.6)0.162
Out-of-hospital CA, n (%)10 (43.4)42 (43.2)0.302
Witnessed CA, n (%)13 (56.5)62 (63.9)0.042
Bystander CPR, n (%)12 (52.2)66 (68.0)0.033
Initial cardiac rhythm, n (%)
VT2 (8.7)6 (6.2)0.607
VF7 (30.4)13 (13.4)0.050
Asystole and pulseless activity3 (13.0)20 (20.6)0.456
Unknown11 (47.8)59 (60.8)0.258
CPR time, min, median (IQR)5.0 (3.0-25.0)17.0 (10.0 -30.0)0.016
Length of ICU stay, d, median (IQR)7.0 (4.0-14.0)5.0 (2.0-15.0)0.268
Laboratory findings, median (IQR)
WBC, ×109/L6.82 (5.45-8.49)12.50 (9.90-20.40)14.30 (9.40-19.70)0.792
Neutrophil ratio, %57.3 (50.2-63.4)84.5 (76.0-90.2)87.2 (81.6-91.2)0.198
PCT, ng/mL0.15 (0.01-0.33)1.00 (0.41-3.67)4.50 (0.83-8.91)0.156
Creatinine, μmol/L64.5 (57.2-79.2)85.5 (62.3-137.5)139.0 (95.0-232.0)0.158
High sensitivity troponin I, μg/L0.01 (0.00-0.03)0.17 (0.07-1.13)0.78 (0.18-7.97)0.081
BNP, pg/mL30.8 (22.3-45.9)444.3 (83.6-1154.0)702.0 (185.1-2066.3)0.270
PO2/FiO2, mmHg460.0 (410.8-482.0)347.0 (262.9-402.6)214.0 (152.0-360.0)0.314
Blood glucose, μmol/L5.2 (4.7-5.7)7.1 (4.2-9.9)10.6 (6.1-13.6)0.128
APACHE II score, median (IQR)13.0 (9.0-18.0)23.0 (18.0-25.0)<0.01
SOFA score, median (IQR)6.0 (2.0-9.3)12.0 (10.0-14.0)0.011

IQR: interquartile range; ICU: intensive care unit; CA: cardiac arrest; CPR: cardiopulmonary resuscitation; VF: ventricular fibrillation; VT: ventricular tachycardia; WBC: white blood cell; PCT: procalcitonin; BNP: brain natriuretic peptide; PO2/FiO2: partial pressure of oxygen/ fraction of inspiration oxygen; APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; a: P values for the comparison of good neurological outcome and poor neurological outcome groups.

New window| CSV


Comparisons of serum glucose metabolic reprogramming-related parameters, NSE, IL-6, APACHE II and SOFA scores among the three groups

Serum levels of glucose metabolic reprogramming-related parameters (LDH, lactate, pyruvate and lactate/pyruvate ratio), NSE and IL-6 on day 1 after ICU admission were significantly increased in patients after ROSC than in healthy volunteers (Figure 1, supplementary Table 1). On days 3 and 7 after ROSC, the serum levels of LDH, pyruvate, NSE and IL-6 and lactate/pyruvate ratio were still high, except for the serum lactate, which recovered to near the baseline level. However, on days 1, 3 and 7 after ROSC, all the above parameters, as well as the APACHE II score and the SOFA score, were significantly higher in non-survivors compared with survivors.

Figure 1.

Figure 1.   Comparisons of the serum LDH (A), lactate (B), pyruvate (C), lactate/pyruvate ratio (D), NSE (E), IL-6 (F), APACHE II (G) and SOFA (H) scores among healthy volunteers, survivors and non-survivors. LDH: lactate dehydrogenase; NSE: neuron-specific enolase; IL-6: interleukin-6; APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; ROSC: restoration of spontaneous circulation; *P<0.05 versus healthy volunteers; #P<0.05 versus survivors.


Associations of serum glucose metabolic reprogramming-related parameters, NSE, IL-6, APACHE II score, and SOFA score with 28-day poor neurological prognosis and all-cause mortality

We defined 28-day poor neurological prognosis and 28-day all-cause mortality as dependent variables and serum LDH, lactate, pyruvate, lactate/pyruvate ratio, NSE, IL-6, APACHE II score, SOFA score on days 1, 3 and 7 after ROSC, as well as witnessed CA, bystander CPR, initial rhythm, and CPR time as independent variables. The results of the multivariate regression analysis indicated that the serum LDH, pyruvate, IL-6, APACHE II score, and SOFA score on days 1, 3 and 7 after ROSC; the serum lactate level on day 3 after ROSC; the serum NSE on days 1 and 3 after ROSC; and the lactate/pyruvate ratio on day 1 after ROSC, as well as an unknown initial rhythm, were significantly associated with 28-day poor neurological prognosis and 28-day all-cause mortality (supplementary Table 2).

Predictive values of serum glucose metabolic reprogramming-related parameters, NSE, IL-6, APACHE II and SOFA scores for 28-day poor neurological prognosis and all-cause mortality

ROC analysis revealed that serum LDH, pyruvate, lactate/pyruvate ratio, IL-6, NSE, SOFA score and APACHE II score on days 1, 3 and 7 after ROSC were potential predictors of both 28-day poor neurological prognosis (Figure 2A and B and supplementary Table 3) and 28-day all-cause mortality (Figure 2C and D and supplementary Table 4). DeLong’s test showed that NSE had the largest AUC (all P<0.05), while the AUC of LDH was closest to that of NSE on days 1, 3 and 7 after ROSC, but the AUCs of both were significantly larger than those of pyruvate, lactate/pyruvate ratio, IL-6, APACHE II score and SOFA score. Supplementary Tables 3 and 4 show the performances for predicting 28-day neurological prognosis and all-cause mortality.

Figure 2.

Figure 2.   Receiver operating characteristic curves of serum LDH on days 1, 3, and 7 after ROSC as well as LDH, pyruvate, NSE, IL-6, APACHE II score, SOFA score, and L/P ratio on day 1 after ROSC for the prediction of poor 28-day neurological prognosis (A, B) and 28-day all-cause mortality (C, D). AUC: area under the curve; LDH: lactate dehydrogenase; NSE: neuron-specific enolase; IL-6: interleukin-6; APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; L/P ratio: lactate/pyruvate ratio.


DISCUSSION

The present study revealed a significant increase in glucose metabolic reprogramming-related parameters in patients after ROSC, including serum LDH, lactate and pyruvate levels and lactate/pyruvate ratio, which were higher in non-survivors than in survivors. Furthermore, these increased parameters, except for serum lactate, all had independent predictive values for 28-day poor neurological prognosis and 28-day all-cause mortality after ROSC.

Glycolysis is increased during both ischemia and reperfusion in response to the demand for energy.[12,13] It has long been accepted that anaerobic glycolysis plays a major role in energy production during CA (no-flow) and CPR (low-flow), concurrent with significantly elevated serum levels of lactate.[12] Notably, we still observed a significant increase in the serum lactate level on day 1 after ROSC, with a higher level in non-survivors than in survivors in the first week after ROSC. This elevated lactate level might mainly be resulted from both increased anaerobic and aerobic glycolysis. The capillary no-reflow phenomenon has been found in the brain, heart, kidney, skeletal muscle, and small intestine after ischemia, which may become even worse during reperfusion, leading to a failure of nutritive perfusion characterized by a decrease in the number of perfused capillaries and an increase in anaerobic glycolysis.[12] In addition, the elevation of serum lactate level during reperfusion may also be related to potential vital organ ischemia (hypoperfusion) resulting from low cardiac output, which may further cause anaerobic glycolysis. However, aerobic glycolysis (namely, glucose metabolic reprogramming) also occurs during reperfusion even when oxygen levels and delivery are adequate.[14,15] The mechanisms of glucose metabolic reprogramming during reperfusion could be associated with an inhibition of pyruvate dehydrogenase, which leads to the uncoupling of glycolysis and glucose oxidation and a decrease in glucose oxidation,[7] an upregulation of glycolysis-promoting enzyme expression (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3, PFKFB3),[14] adrenergic regulation and influence of norepinephrine on astrocytic metabolism,[15] mitochondrial dysfunction,[16] and an increase in synaptic activity.[17] Notably, aerobic glycolysis is crucial for the activation of several immune cell functions to meet the increased energy requirements of these cells.[5,18] As a result, the increased serum lactate levels could also originate from activated immune cells undergoing aerobic glycolysis due to a systemic inflammatory response after ROSC similar to that of sepsis,[18,19] as evidenced by the elevated serum IL-6 levels in this study.

Serum lactate, a product of glycolysis, can be measured quickly and easily in clinical settings and is a biomarker of tissue hypoxia. Recent studies have demonstrated that it has superior predictive values in patients who were suffering from sepsis, trauma, or other critical illnesses.[20-22] A multicenter prospective cohort study showed that out-of-hospital CA patients with high serum lactate levels during CPR (low-flow) had poor 1-month survival, particularly patients with a non-shockable rhythm.[23] Nevertheless, the association of increased serum lactate levels at the early phase after ROSC (reperfusion stage) with poor CA patient outcomes is controversial.[24-27] Our logistical regression analysis revealed that initial levels of serum lactate after ROSC were not associated with poor neurological prognosis or all-cause mortality in CA patients, similar to the findings of some previous studies.[26,27] In contrast to our findings, two studies revealed that initial levels of serum lactate after ROSC could predict poor neurological prognosis and/or mortality in CA patients.[24,25] The discrepancy in the above findings might be explained by the following reasons. First, the present study had a small sample size, so the associations of initial serum lactate levels with poor neurological prognosis and all-cause mortality might not reach statistical significance despite a higher lactate level in non-survivors than in survivors. Second, in the study by Punniyakotty et al,[25] the serum lactate level was independently associated with survival in non-traumatic OHCA patients only when ammonia was excluded. Third, recent studies have confirmed the beneficial effects of elevated lactate, including the supply of lactate from astrocytic aerobic glycolysis for neuronal energy metabolism (a mechanism so-called the astrocyte-neuron lactate shuttle), as well as that the lactate is a signaling molecule in the brain that links metabolism, substrate availability, blood flow, and neuronal activity.[28,29] Thus, future multicenter prospective trials with large sample sizes are needed to determine the exact relationship between increased serum lactate levels early after ROSC and poor outcomes.

Pyruvate is an intermediary metabolic product of glycolysis. It is irreversibly converted to acetyl-CoA under the catalysis of pyruvate dehydrogenase kinase, thereby functioning as the primary link between glycolysis and the tricarboxylic acid cycle, or reversibly converted to lactate under the catalysis of LDH. Pyruvate has been demonstrated to sharply decrease during CA.[30] However, we observed a slight increase in serum pyruvate at the early stage after ROSC, with a gradual recovery to a normal level, which is similar to the findings of some previous studies.[29,31] The lactate/pyruvate ratio is considered to be a sensitive, nonspecific, reliable ischemia/hypoxia index in critically ill patients.[32] Likewise, a significant increase in the lactate/pyruvate ratio was observed in this study on day 1, with a gradual decrease in the first week after ROSC, as supported by other studies.[29,30] In addition, both the serum pyruvate concentration and the lactate/pyruvate ratio were higher in non-survivors than survivors, which were independently associated with poor 28-day neurological prognosis and 28-day all-cause mortality after ROSC, with superior predictive values. The increase in serum pyruvate may be associated with an increase in pyruvate production due to the recovery of glycolytic substrates after reperfusion and with a decrease in the oxidative decarboxylation of pyruvate due to mitochondrial dysfunction after I/R injury.[33]

As a glycolytic enzyme that reversibly converts pyruvate to lactate, LDH is found extensively in blood cells, the brain, heart, muscle, and other tissues of the body. Large quantities of LDH can be released into the circulation following cellular damage, making LDH an important cell injury-related marker commonly observed in patients with hypoxic ischemic brain injury due to ischemia or inflammatory responses. Furthermore, elevated serum LDH is considered to be associated with extensive tissue damage and poor outcomes in patients with sepsis, coronavirus disease 2019, and out-of-hospital CA.[11,34,35] Our study also revealed a significant difference in serum LDH between the non-survivor and survivor groups after ROSC. Notably, the predictive performance of LDH in the first week post-ROSC for 28-day poor neurological prognosis and all-cause mortality was closest to that of NSE. NSE is the most commonly used biomarker for prognostication after CA. Despite its sensitivity and specificity ranking second to those of NSE, serum LDH testing is more widely available and less expensive. Therefore, among the serum glucose metabolic reprogramming-related parameters, LDH had the best predictive performance and might also be the most promising for future clinical applications.

Limitations

There were also several limitations to this study. First, this was a single-center study with strict exclusion criteria, and the study period was short, which led to a relatively small sample size. Second, an assessment of total LDH was conducted on peripheral blood, which may not adequately reflect brain and heart isoenzyme status. Finally, LDH expression has been demonstrated to be affected by mild hypothermia.[36]

CONCLUSIONS

The serum parameters related to glucose metabolic reprogramming were significantly increased after ROSC. Increased serum LDH and pyruvate levels and lactate/pyruvate ratio could predict 28-day poor neurological prognosis and all-cause mortality after ROSC, and the predictive efficacy of LDH was superior among the parameters.

Funding: This study was funded by the Shenzhen Science and Technology Program (JCYJ20230807112007014) and Shenzhen Key Medical Discipline Construction Fund (SZXK046).

Ethical approval: Study approval was obtained from the Medical Ethics Committee at the First Affiliated Hospital of Dalian Medical University (PJ-KS-KY-2021-214), and written informed consent was obtained from all subjects or their legal guardians.

Conflicts of interest: The authors declare no conflicts of interest.

Contributors: SA (Subi Abudurexiti) and SHX (Shihai Xu) contributed equally to this work as co-first authors. GP: concept and design; SHX and SA: statistical analysis; PG: funding; ZPS and SA: drafting of the article; ZPS, YJ and SA: data collection. All authors revised the article and approved the final version of the article.

The supplementary files in this paper are available at http://wjem.com.cn.

Reference

Birkun A.

Understanding the epidemiology and outcomes of out-of-hospital cardiac arrest in the former Union of Soviet Socialist Republics: observations from the Crimean peninsula

World J Emerg Med. 2022; 13(1):67-8.

DOI:10.5847/wjem.j.1920-8642.2022.009      PMID:35003419      [Cited within: 1]

Yan SJ, Chen M, Wen J, Fu WN, Song XY, Chen HJ, et al.

Global research trends in cardiac arrest research: a visual analysis of the literature based on CiteSpace

World J Emerg Med. 2022; 13(4):290-6.

[Cited within: 1]

Martin E, Rosenthal RE, Fiskum G.

Pyruvate dehydrogenase complex: metabolic link to ischemic brain injury and target of oxidative stress

J Neurosci Res. 2005; 79(1-2): 240-7.

PMID:15562436      [Cited within: 1]

The mammalian pyruvate dehydrogenase complex (PDHC) is a mitochondrial matrix enzyme complex (greater than 7 million Daltons) that catalyzes the oxidative decarboxylation of pyruvate to form acetyl CoA, nicotinamide adenine dinucleotide (the reduced form, NADH), and CO(2). This reaction constitutes the bridge between anaerobic and aerobic cerebral energy metabolism. PDHC enzyme activity and immunoreactivity are lost in selectively vulnerable neurons after cerebral ischemia and reperfusion. Evidence from experiments carried out in vitro suggests that reperfusion-dependent loss of activity is caused by oxidative protein modifications. Impaired enzyme activity may explain the reduced cerebral glucose and oxygen consumption that occurs after cerebral ischemia. This hypothesis is supported by the hyperoxidation of mitochondrial electron transport chain components and NAD(H) that occurs during reperfusion, indicating that NADH production, rather than utilization, is rate limiting. Additional support comes from the findings that immediate postischemic administration of acetyl-L-carnitine both reduces brain lactate/pyruvate ratios and improves neurologic outcome after cardiac arrest in animals. As acetyl-L-carnitine is converted to acetyl CoA, the product of the PDHC reaction, it follows that impaired production of NADH is due to reduced activity of either PDHC or one or more steps in glycolysis. Impaired cerebral energy metabolism and PDHC activity are associated also with neurodegenerative disorders including Alzheimer's disease and Wernicke-Korsakoff syndrome, suggesting that this enzyme is an important link in the pathophysiology of both acute brain injury and chronic neurodegeneration.(c) 2004 Wiley-Liss, Inc.

Suetrong B, Walley KR.

Lactic acidosis in sepsis: it’s not all anaerobic: implications for diagnosis and management

Chest. 2016; 149(1):252-61.

DOI:10.1378/chest.15-1703      PMID:26378980      [Cited within: 1]

Increased blood lactate concentration (hyperlactatemia) and lactic acidosis (hyperlactatemia and serum pH < 7.35) are common in patients with severe sepsis or septic shock and are associated with significant morbidity and mortality. In some patients, most of the lactate that is produced in shock states is due to inadequate oxygen delivery resulting in tissue hypoxia and causing anaerobic glycolysis. However, lactate formation during sepsis is not entirely related to tissue hypoxia or reversible by increasing oxygen delivery. In this review, we initially outline the metabolism of lactate and etiology of lactic acidosis; we then address the pathophysiology of lactic acidosis in sepsis. We discuss the clinical implications of serum lactate measurement in diagnosis, monitoring, and prognostication in acute and intensive care settings. Finally, we explore treatment of lactic acidosis and its impact on clinical outcome. Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

van Wyngene L, Vandewalle J, Libert C.

Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?

EMBO Mol Med. 2018; 10(8): e8712.

[Cited within: 2]

Vaupel P, Multhoff G.

Revisiting the Warburg effect: historical dogma versus current understanding

J Physiol. 2021; 599(6):1745-57.

[Cited within: 1]

Schöder H, Knight RJ, Kofoed KF, Schelbert HR, Buxton DB.

Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium

Biochim Biophys Acta. 1998; 1406(1):62-72.

PMID:9545535      [Cited within: 2]

Pyruvate dehydrogenase (PDH) is regulated both by covalent modification and through modulation of the active enzyme by metabolites. In the isolated heart, post-ischaemic inhibition of PDH, leading to uncoupling of glycolysis and glucose oxidation and a decrease in cardiac efficiency, has been described. In vivo, post-ischaemic reperfusion leads to metabolic abnormalities consistent with PDH inhibition, but the effects of ischaemia/reperfusion on PDH are not well characterized. We therefore investigated PDH regulation following transient ischaemia in vivo. In 33 open-chest dogs, the left anterior descending (LAD) was occluded for 20 min followed by 4 h reperfusion. In 17 dogs, dichloroacetate (DCA) was injected prior to reperfusion, while 16 dogs served as controls. In dogs without DCA, glucose oxidation and lactate uptake were lower in reperfused than in remote tissue, suggesting reduced flux through PDH. However, percent active and total PDH measured in myocardial biopsies were similar in both territories, excluding covalent enzyme modification or loss of functional enzyme. DCA activated PDH activity similarly in both regions and abolished differences in glucose oxidation and lactate uptake. Thus, decreased PDH flux in reperfused myocardium does not result from covalent modification or loss of total enzyme activity, but more likely from metabolite inhibition of the active enzyme. DCA leads to essentially complete activation of PDH, increases overall glucose utilization and abolishes post-ischaemic inhibition of glucose oxidation.

Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, et al.

Part 4: advanced life support: 2015 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations

Circulation. 2015; 132(16 Suppl 1):S84-S145.

[Cited within: 1]

Soar J, Berg KM, Andersen LW, Böttiger BW, Cacciola S, Callaway CW, et al.

Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations

Resuscitation. 2020; 156:A80-A119.

DOI:10.1016/j.resuscitation.2020.09.012      PMID:33099419      [Cited within: 1]

This 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations for advanced life support includes updates on multiple advanced life support topics addressed with 3 different types of reviews. Topics were prioritized on the basis of both recent interest within the resuscitation community and the amount of new evidence available since any previous review. Systematic reviews addressed higher-priority topics, and included double-sequential defibrillation, intravenous versus intraosseous route for drug administration during cardiac arrest, point-of-care echocardiography for intra-arrest prognostication, cardiac arrest caused by pulmonary embolism, postresuscitation oxygenation and ventilation, prophylactic antibiotics after resuscitation, postresuscitation seizure prophylaxis and treatment, and neuroprognostication. New or updated treatment recommendations on these topics are presented. Scoping reviews were conducted for anticipatory charging and monitoring of physiological parameters during cardiopulmonary resuscitation. Topics for which systematic reviews and new Consensuses on Science With Treatment Recommendations were completed since 2015 are also summarized here. All remaining topics reviewed were addressed with evidence updates to identify any new evidence and to help determine which topics should be the highest priority for systematic reviews in the next 1 to 2 years.Copyright © 2020. Published by Elsevier B.V.

Hellmann F, Verdi M, Schlemper BR Jr, Caponi S.

50th anniversary of the Declaration of Helsinki: the double standard was introduced

Arch Med Res. 2014; 45(7):600-1.

DOI:10.1016/j.arcmed.2014.10.005      PMID:25450586      [Cited within: 1]

The Declaration of Helsinki (DoH), adopted by the World Medical Association (WMA), is one of the most influential international documents in research ethics, is turning 50 in 2014. Its regular updates, seven versions (1975, 1983, 1989, 1996, 2000, 2008, 2013) and two notes of clarification (2002, 2004), characterize it as a 'live' document. The seventh version of the DoH was amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. The new version was reorganized and restructured, with paragraphs subdivided and regrouped. However, the DoH remains controversial and some ethical issues are still uncovered. The major problem was the insertion of the phrase 'less effective than the best proven' on placebo paragraph in order to allow double standard in medical research in low-resource countries. The DoH is a 'live' document, which will continually have to deal with new topics and challenges. Health equity needs to be a priority, and with that, a single ethical standard for medical research. Copyright © 2014 IMSS. Published by Elsevier Inc. All rights reserved.

Lu J, Wei ZH, Jiang H, Cheng L, Chen QH, Chen MQ, et al.

Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study

J Surg Res. 2018; 228:314-21.

DOI:S0022-4804(18)30198-7      PMID:29907227      [Cited within: 2]

Sepsis is a major health care problem, which affects millions of people around the world. Glucose metabolic reprogramming of immune cells plays a crucial role during advancement of sepsis. However, the association between glucose metabolic reprogramming and mortality in patients with sepsis is unclear. Lactate dehydrogenase (LDH) catalyzes the last step of glycolysis. Investigating the relationship between LDH and mortality is important to understand the effect of metabolic reprogramming on prognosis of patients with sepsis.A total of 192 patients with sepsis were included in our study. Data on characteristics of patients, biochemical variables, and inflammatory mediator were collected. Association between the level of serum LDH and 28-day mortality was also analyzed. The correlations between serum LDH, interleukin-1β, creatinine, PaO/FiO, and lactate were also observed. The association between LDH and the risk of death was further analyzed. Moreover, receiver operating characteristic curve was depicted to compare the accuracy in prediction of LDH and other variables.There were statistic difference in 28-day mortality between elevated LDH group and normal LDH group (P = 0.021). Level of serum LDH was an independent risk factor for death of patients with sepsis (hazard ratio 1.005, 95% confidence interval 1.002-1.007, P = 0.001). There were significant correlations between LDH, interleukin-1β (r = 0.514, P = 0.000), creatinine (r = 0.368, P = 0.000), PaO/FiO (r = -0.304, P = 0.000), and lactate (r = 0.560, P = 0.000). The receiver operating characteristic curves showed that the area under the LDH curve for prediction for mortality was 0.783.Serum LDH is probably associated with 28-day mortality in patients with sepsis.Copyright © 2018 Elsevier Inc. All rights reserved.

Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/reperfusion. Compr Physiol. 2016; 7(1):113-70.

[Cited within: 3]

Issa MS, Grossestreuer AV, Patel H, Ntshinga L, Coker A, Yankama T, et al.

Lactate and hypotension as predictors of mortality after in-hospital cardiac arrest

Resuscitation. 2021; 158:208-14.

DOI:10.1016/j.resuscitation.2020.10.018      PMID:33289651      [Cited within: 1]

Guidance on post-cardiac arrest prognostication is largely based on data from out-of-hospital cardiac arrest (OHCA), despite clear differences between the OHCA and in-hospital cardiac arrest (IHCA) populations. Early prediction of mortality after IHCA would be useful to help make decisions about post-arrest care. We evaluated the ability of lactate and need for vasopressors after IHCA to predict hospital mortality.Single center retrospective observational study of adult IHCA patients who achieved sustained return of spontaneous circulation (ROSC), required mechanical ventilation peri-arrest and had a lactate checked within 2 h after ROSC. We evaluated the association of post-ROSC lactate and need for vasopressors with mortality using multivariate logistic regression.A total of 364 patients were included. Patients who received vasopressors within 3 h after ROSC had significantly higher mortality compared to patients who did not receive vasopressors (58% vs. 43%, p = 0.03). Elevated lactate level was associated with mortality (44% if lactate <5 mmol/L, 58% if lactate 5-10 mmol/L, and 73% if lactate >10 mmol/L, p < 0.01). A multivariable model with lactate group and post-ROSC vasopressor use as predictors demonstrated moderate discrimination (AUC 0.64 [95%CI:0.59-0.70]). Including other variables, the most parsimonious model included lactate, age, body mass index, race, and history of arrhythmia, cancer and/or liver disease (AUC 0.70 [95% CI: 0.64-0.75]).Post-ROSC lactate and need for vasopressors may be helpful in stratifying mortality risk in patients requiring mechanical ventilation after IHCA.Copyright © 2020 Elsevier B.V. All rights reserved.

Li ZF, Zhang B, Yao WL, Zhang CH, Wan L, Zhang Y.

APC-Cdh1 regulates neuronal apoptosis through modulating glycolysis and pentose-phosphate pathway after oxygen-glucose deprivation and reperfusion

Cell Mol Neurobiol. 2019; 39(1):123-35.

DOI:10.1007/s10571-018-0638-x      PMID:30460429      [Cited within: 2]

Anaphase-promoting complex (APC) with its coactivator Cdh1 is required to maintain the postmitotic state of neurons via degradation of Cyclin B1, which aims to prevent aberrant cell cycle entry that causes neuronal apoptosis. Interestingly, evidence is accumulating that apart from the cell cycle, APC-Cdh1 also involves in neuronal metabolism via modulating the glycolysis promoting enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). Here, we showed that under oxygen-glucose deprivation and reperfusion (OGD/R), APC-Cdh1 was decreased in primary cortical neurons. Likewise, the neurons exhibited enhanced glycolysis when oxygen supply was reestablished during reperfusion, which was termed as the "neuronal Warburg effect." In particular, the reperfused neurons showed elevated PFKFB3 expression in addition to a reduction in glucose 6-phosphate dehydrogenase (G6PD). Such changes directed neuronal glucose metabolism from pentose-phosphate pathway (PPP) to aerobic glycolysis compared to the normal neurons, resulting in increased ROS production and apoptosis during reperfusion. Pretreatment of neurons with Cdh1 expressing lentivirus before OGD could reverse this metabolic shift and attenuated ROS-induced apoptosis. However, the metabolism regulation and neuroprotection by Cdh1 under OGD/R condition could be blocked when co-transfecting neurons with Ken box-mut-PFKFB3 (which is APC-Cdh1 insensitive). Based on these data, we suggest that the Warburg effect may contribute to apoptotic mechanisms in neurons under OGD/R insult, and targeting Cdh1 may be a potential therapeutic strategy as both glucose metabolic regulator and apoptosis suppressor of neurons in brain injuries.

Dienel GA, Cruz NF.

Aerobic glycolysis during brain activation: adrenergic regulation and influence of norepinephrine on astrocytic metabolism

J Neurochem. 2016; 138(1):14-52.

DOI:10.1111/jnc.13630      PMID:27166428      [Cited within: 2]

Aerobic glycolysis occurs during brain activation and is characterized by preferential up-regulation of glucose utilization compared with oxygen consumption even though oxygen level and delivery are adequate. Aerobic glycolysis is a widespread phenomenon that underlies energetics of diverse brain activities, such as alerting, sensory processing, cognition, memory, and pathophysiological conditions, but specific cellular functions fulfilled by aerobic glycolysis are poorly understood. Evaluation of evidence derived from different disciplines reveals that aerobic glycolysis is a complex, regulated phenomenon that is prevented by propranolol, a non-specific β-adrenoceptor antagonist. The metabolic pathways that contribute to excess utilization of glucose compared with oxygen include glycolysis, the pentose phosphate shunt pathway, the malate-aspartate shuttle, and astrocytic glycogen turnover. Increased lactate production by unidentified cells, and lactate dispersal from activated cells and lactate release from the brain, both facilitated by astrocytes, are major factors underlying aerobic glycolysis in subjects with low blood lactate levels. Astrocyte-neuron lactate shuttling with local oxidation is minor. Blockade of aerobic glycolysis by propranolol implicates adrenergic regulatory processes including adrenal release of epinephrine, signaling to brain via the vagus nerve, and increased norepinephrine release from the locus coeruleus. Norepinephrine has a powerful influence on astrocytic metabolism and glycogen turnover that can stimulate carbohydrate utilization more than oxygen consumption, whereas β-receptor blockade 're-balances' the stoichiometry of oxygen-glucose or -carbohydrate metabolism by suppressing glucose and glycogen utilization more than oxygen consumption. This conceptual framework may be helpful for design of future studies to elucidate functional roles of preferential non-oxidative glucose utilization and glycogen turnover during brain activation. Aerobic glycolysis, the preferential up-regulation of glucose utilization (CMRglc ) compared with oxygen consumption (CMRO2 ) during brain activation, is blocked by propranolol. Epinephrine release from the adrenal gland stimulates vagus nerve signaling to the locus coeruleus, enhancing norepinephrine release in the brain, and regulation of astrocytic and neuronal metabolism to stimulate CMRglc more than CMRO2. Propranolol suppresses CMRglc more than CMRO2.© 2016 International Society for Neurochemistry.

Seppet E, Gruno M, Peetsalu A, Gizatullina Z, Nguyen HP, Vielhaber S, et al.

Mitochondria and energetic depression in cell pathophysiology

Int J Mol Sci. 2009; 10(5):2252-303.

DOI:10.3390/ijms10052252      PMID:19564950      [Cited within: 1]

Mitochondrial dysfunction is a hallmark of almost all diseases. Acquired or inherited mutations of the mitochondrial genome DNA may give rise to mitochondrial diseases. Another class of disorders, in which mitochondrial impairments are initiated by extramitochondrial factors, includes neurodegenerative diseases and syndromes resulting from typical pathological processes, such as hypoxia/ischemia, inflammation, intoxications, and carcinogenesis. Both classes of diseases lead to cellular energetic depression (CED), which is characterized by decreased cytosolic phosphorylation potential that suppresses the cell's ability to do work and control the intracellular Ca(2+) homeostasis and its redox state. If progressing, CED leads to cell death, whose type is linked to the functional status of the mitochondria. In the case of limited deterioration, when some amounts of ATP can still be generated due to oxidative phosphorylation (OXPHOS), mitochondria launch the apoptotic cell death program by release of cytochrome c. Following pronounced CED, cytoplasmic ATP levels fall below the thresholds required for processing the ATP-dependent apoptotic cascade and the cell dies from necrosis. Both types of death can be grouped together as a mitochondrial cell death (MCD). However, there exist multiple adaptive reactions aimed at protecting cells against CED. In this context, a metabolic shift characterized by suppression of OXPHOS combined with activation of aerobic glycolysis as the main pathway for ATP synthesis (Warburg effect) is of central importance. Whereas this type of adaptation is sufficiently effective to avoid CED and to control the cellular redox state, thereby ensuring the cell survival, it also favors the avoidance of apoptotic cell death. This scenario may underlie uncontrolled cellular proliferation and growth, eventually resulting in carcinogenesis.

Bas-Orth C, Tan YW, Lau D, Bading H.

Synaptic activity drives a genomic program that promotes a neuronal Warburg effect

J Biol Chem. 2017; 292(13):5183-94.

DOI:10.1074/jbc.M116.761106      PMID:28196867      [Cited within: 1]

Synaptic activity drives changes in gene expression to promote long lasting adaptations of neuronal structure and function. One example of such an adaptive response is the buildup of acquired neuroprotection, a synaptic activity- and gene transcription-mediated increase in the resistance of neurons against harmful conditions. A hallmark of acquired neuroprotection is the stabilization of mitochondrial structure and function. We therefore re-examined previously identified sets of synaptic activity-regulated genes to identify genes that are directly linked to mitochondrial function. In mouse and rat primary hippocampal cultures, synaptic activity caused an up-regulation of glycolytic genes and a concomitant down-regulation of genes required for oxidative phosphorylation, mitochondrial biogenesis, and maintenance. Changes in metabolic gene expression were induced by action potential bursting, but not by glutamate bath application activating extrasynaptic NMDA receptors. The specific and coordinate pattern of gene expression changes suggested that synaptic activity promotes a shift of neuronal energy metabolism from oxidative phosphorylation toward aerobic glycolysis, also known as the Warburg effect. The ability of neurons to up-regulate glycolysis has, however, been debated. We therefore used FACS sorting to show that, in mixed neuron glia co-cultures, activity-dependent regulation of metabolic gene expression occurred in neurons. Changes in gene expression were accompanied by changes in the phosphorylation-dependent regulation of the key metabolic enzyme, pyruvate dehydrogenase. Finally, increased synaptic activity caused an increase in the ratio of l-lactate production to oxygen consumption in primary hippocampal cultures. Based on these data we suggest the existence of a synaptic activity-mediated neuronal Warburg effect that may promote mitochondrial homeostasis and neuroprotection.© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Cheng SC, Joosten LA, Netea MG.

The interplay between central metabolism and innate immune responses

Cytokine Growth Factor Rev. 2014; 25(6):707-13.

[Cited within: 2]

Adrie C, Adib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C, et al.

Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome

Circulation. 2002; 106(5):562-8.

[Cited within: 1]

Haas SA, Lange T, Saugel B, Petzoldt M, Fuhrmann V, Metschke M, et al.

Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients

Intensive Care Med. 2016; 42(2):202-10.

DOI:10.1007/s00134-015-4127-0      PMID:26556617      [Cited within: 1]

Hyperlactatemia may occur for a variety of reasons and is a predictor of poor clinical outcome. However, only limited data are available on the underlying causes of hyperlactatemia and the mortality rates associated with severe hyperlactatemia in critically ill patients. We therefore aimed to evaluate the etiology of severe hyperlactatemia (defined as a lactate level >10 mmol/L) in a large cohort of unselected ICU patients. We also aimed to evaluate the association between severe hyperlactatemia and lactate clearance with ICU mortality.In this retrospective, observational study at an University hospital department with 11 ICUs during the study period between 1 April 2011 and 28 February 2013, we screened 14,040 ICU patients for severe hyperlactatemia (lactate >10 mmol/L).Overall mortality in the 14,040 ICU patients was 9.8 %. Of these, 400 patients had severe hyperlactatemia and ICU mortality in this group was 78.2 %. Hyperlactatemia was associated with death in the ICU [odds ratio 1.35 (95 % CI 1.23; 1.49; p < 0.001)]. The main etiology for severe hyperlactatemia was sepsis (34.0 %), followed by cardiogenic shock (19.3 %), and cardiopulmonary resuscitation (13.8 %). Patients developing severe hyperlactatemia >24 h of ICU treatment had a significantly higher ICU mortality (89.1 %, 155 of 174 patients) than patients developing severe hyperlactatemia ≤ 24 h of ICU treatment (69.9 %, 158 of 226 patients; p < 0.0001). Lactate clearance after 12 h showed a receiver-operating-characteristics area under the curve (ROC-AUC) value of 0.91 to predict ICU mortality (cut-off showing highest sensitivity and specifity was a 12 h lactate clearance of 32.8 %, Youden Index 0.72). In 268 patients having a 12-h lactate clearance <32.8 % ICU mortality was 96.6 %.Severe hyperlactatemia (>10 mmol/L) is associated with extremely high ICU mortality especially when there is no marked lactate clearance within 12 h. In such situations, the benefit of continued ICU therapy should be evaluated.

Mahmoodpoor A, Shadvar K, Saghaleini SH, Koleini E, Hamishehkar H, Ostadi Z, et al.

Which one is a better predictor of ICU mortality in septic patients? Comparison between serial serum lactate concentrations and its removal rate

J Crit Care. 2018; 44:51-6.

DOI:S0883-9441(17)31348-5      PMID:29065350      [Cited within: 1]

To predict 28-day mortality with serum lactate and oxygenation profile in sepsis.82 patients were admitted to the ICU with sepsis. Comorbid disease, hemodynamic and oxygenation parameters were recorded. Serum lactate was measured at T0, T6, T12 and T24 hours of admission. Arterial and venous oxygen saturation levels were also measured. Regression and ROC analyses were used to predict death within 28days.Out of 82 patients, 32 died within 28days of ICU admission. Non-survivors differed from survivors in having higher serum lactate concentrations on admission (0.6mmol/L; P=0.033), requiring more norepinephrine (14μg/min; P<0.001), higher frequency of acute kidney injury, prolonged mechanical ventilation (5-days; P<0.001) and ICU stay (1-day; P=0.029). Saturation of oxygen in arterial (a), central venous blood (cv) and (a-cv) were similar between the survivors and non-survivors. T24 level of lactate was the best predictor of 28-day mortality with 78% sensitivity and 90% specificity (AUC=0.912±0.033).Serial measurements of serum lactate with special emphasis on its concentration at 24hour after admission remains the most predictive of short-term mortality in the ICU. Other predictors of mortality are relatively inferior and must be used collectively in context to better predict the clinical outcome of sepsis.Published by Elsevier Inc.

Parsikia A, Bones K, Kaplan M, Strain J, Leung PS, Ortiz J, et al.

The predictive value of initial serum lactate in trauma patients

Shock. 2014; 42(3):199-204.

DOI:10.1097/SHK.0000000000000208      PMID:24978889      [Cited within: 1]

Trauma patients require early assessment of injury severity. Trauma scores, although well validated, can be unwieldy in the emergency clinical setting. We sought to evaluate the prognostic value of initial serum lactate (ISL) for mortality, operative intervention (OI), and intensive care unit admission (ICUA) in trauma patients. We conducted an institutional review board-approved retrospective study. We reviewed all trauma patients between January 2007 and June 2012 in our prospectively maintained database. We included only adults whose ISL had been drawn within the first 35 min after arrival. We included only those patients whose interval between injury and arrival was within 24 h. Survivors and nonsurvivors were compared using logistic regression, Mann-Whitney U, and chi-square tests. Discriminating ability of ISL for mortality was assessed with receiver operating characteristic analysis. Our secondary outcomes (ICUA and OI) were evaluated with logistic regression test and receiver operating characteristic analysis. A total of 1,941 patients were included. Overall mortality was 6.2%. Median ISL was 32 mg/dL (interquartile range, 17 - 62) for nonsurvivors versus 21 mg/dL (interquartile range, 14 - 32) for survivors (P < 0.001). In multivariate analysis, ISL was a significant covariate for mortality (P = 0.015). The odds ratio was 1.010 (95% confidence interval, 1.002 - 1.019). The area under the curve was 0.63. The ISL was a significant covariate for OI (P = 0.033). The ISL did not reach significance for ICUA. The ISL is an easily measured, rapid, and inexpensive test that can help to quickly stratify injury severity in trauma patients. We have found that ISL, when used in strictly selected patients, can predict OI and mortality.

Nishioka N, Kobayashi D, Izawa J, Irisawa T, Yamada T, Yoshiya K, et al.

Association between serum lactate level during cardiopulmonary resuscitation and survival in adult out-of-hospital cardiac arrest: a multicenter cohort study

Sci Rep. 2021; 11(1): 1639.

DOI:10.1038/s41598-020-80774-4      PMID:33452306      [Cited within: 1]

We aimed to investigate the association between serum lactate levels during cardiopulmonary resuscitation (CPR) and survival in patients with out-of-hospital cardiac arrest (OHCA). From the database of a multicenter registry on OHCA patients, we included adult nontraumatic OHCA patients transported to the hospital with ongoing CPR. Based on the serum lactate levels during CPR, the patients were divided into four quartiles: Q1 (≤ 10.6 mEq/L), Q2 (10.6-14.1 mEq/L), Q3 (14.1-18.0 mEq/L), and Q4 (> 18.0 mEq/L). The primary outcome was 1-month survival. Among 5226 eligible patients, the Q1 group had the highest 1-month survival (5.6% [74/1311]), followed by Q2 (3.6% [47/1316]), Q3 (1.7% [22/1292]), and Q4 (1.0% [13/1307]) groups. In the multivariable logistic regression analysis, the adjusted odds ratio of Q4 compared with Q1 for 1-month survival was 0.24 (95% CI 0.13-0.46). 1-month survival decreased in a stepwise manner as the quartiles increased (p for trend < 0.001). In subgroup analysis, there was an interaction between initial rhythm and survival (p for interaction < 0.001); 1-month survival of patients with a non-shockable rhythm decreased when the lactate levels increased (p for trend < 0.001), but not in patients with a shockable rhythm (p for trend = 0.72). In conclusion, high serum lactate level during CPR was associated with poor 1-month survival in OHCA patients, especially in patients with non-shockable rhythm.

Lee DH, Cho IS, Lee SH, Min YI, Min JH, Kim SH, et al.

Correlation between initial serum levels of lactate after return of spontaneous circulation and survival and neurological outcomes in patients who undergo therapeutic hypothermia after cardiac arrest

Resuscitation. 2015; 88:143-9.

DOI:10.1016/j.resuscitation.2014.11.005      PMID:25450570      [Cited within: 2]

We analysed the relationship between serum levels of lactate within 1h of return of spontaneous circulation (ROSC) and survival and neurological outcomes in patients who underwent therapeutic hypothermia (TH).This was a multi-centre retrospective and observational study that examined data from the first Korean Hypothermia Network (KORHN) registry from 2007 to 2012. The inclusion criteria were out-of-hospital cardiac arrest (OHCA) and examination of serum levels of lactate within 1h after ROSC, taken from KORHN registry data. The primary endpoint was survival outcome at hospital discharge, and the secondary endpoint was poor neurological outcome (Cerebral Performance Category, CPC, 3-5) at hospital discharge. Initial lactate levels and other variables collected within 1h of ROSC were analysed via multivariable logistic regression.Data from 930 cardiac arrest patients who underwent TH were collected from the KORHN registry. In a total of 443 patients, serum levels of lactate were examined within 1h of ROSC. In-hospital mortality was 289/443 (65.24%), and 347/443 (78.33%) of the patients had CPCs of 3-5 upon hospital discharge. The odds ratios of lactate levels for CPC and in-hospital mortality were 1.072 (95% confidence interval (CI) 1.026-1.121) and 1.087 (95% CI=1.031-1.147), respectively, based on multivariate ordinal logistic regression analyses.High levels of lactate in serum measured within 1h of ROSC are associated with hospital mortality and high CPC scores in cardiac arrest patients treated with TH.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Punniyakotty B, Ong XL, Ahmad M, Kirresh A.

Improving mortality in pediatric out-of-hospital cardiac arrest events requires a multifactorial approach

JACC Asia. 2023; 3(1):166.

DOI:10.1016/j.jacasi.2022.11.011      PMID:36873764      [Cited within: 3]

Starodub R, Abella BS, Grossestreuer AV, Shofer FS, Perman SM, Leary M, et al.

Association of serum lactate and survival outcomes in patients undergoing therapeutic hypothermia after cardiac arrest

Resuscitation. 2013; 84(8):1078-82.

DOI:10.1016/j.resuscitation.2013.02.001      PMID:23402966      [Cited within: 2]

Recent studies have suggested that serum lactate may serve as a marker to predict mortality after resuscitation from cardiac arrest (CA). The relationship between serum lactate and CA outcomes requires further characterization, especially among patients treated with therapeutic hypothermia (TH) and aggressive post-arrest care.A retrospective analysis of patients resuscitated from non-traumatic CA at three urban U.S. hospitals was performed using an established internet-based post-arrest registry. Adult (≥ 18 years) patients resuscitated from CA and receiving TH treatment were included. Logistic regression analysis was used to adjust for potential confounders to survival outcomes. Survival to discharge served as the primary endpoint.A total of 199 post-CA patients treated with TH between 5/2005 and 11/2011 were included in this analysis. The mean age was 56.9 ± 16.5 years, 85/199 (42.7%) patients were female, and survival to discharge was attained in 84/199 (42.2%). While lower initial post-CA serum lactate levels were not associated with increased survival to discharge, subsequent lactate measurements were significantly associated with outcomes (24-h serum lactate levels in survivors vs. non-survivors, 2.7 ± 0.5 vs. 4.2 ± 0.4 mmol/L, p<0.01). Multivariable logistic regression confirmed this relationship with survival to discharge (p<0.01).Lower serum lactate levels at 12h and 24h, but not initially following cardiac arrest, are associated with survival to hospital discharge after resuscitation from CA and TH treatment. Prospective investigation of serum lactate as a potential prognostic tool in CA is needed.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Lee TR, Kang MJ, Cha WC, Shin TG, Sim MS, Jo IJ, et al.

Better lactate clearance associated with good neurologic outcome in survivors who treated with therapeutic hypothermia after out-of-hospital cardiac arrest

Crit Care. 2013; 17(5): R260.

[Cited within: 2]

Riske L, Thomas RK, Baker GB, Dursun SM.

Lactate in the brain:an update on its relevance to brain energy, neurons, glia and panic disorder

Ther Adv Psychopharmacol. 2017; 7(2): 85-9.

[Cited within: 1]

Ji J, Qian SY, Liu J, Gao HM.

Occurrence of early epilepsy in children with traumatic brain injury: a retrospective study

World J Pediatr. 2022; 18(3):214-21.

DOI:10.1007/s12519-021-00502-4      PMID:35150398      [Cited within: 3]

Early post-traumatic seizures (EPTS) refer to epileptic seizures occurring within one week after brain injury. This study aimed to define the risk factors of EPTS and the protective factors that could prevent its occurrence.This is a single-center retrospective study in the PICU, Beijing Children's Hospital. Patients diagnosed with traumatic brain injury (TBI), admitted with and without EPTS between January 2016 and December 2020 were included in the study.We included 108 patients diagnosed with TBI. The overall EPTS incidence was 33.98% (35/108). The correlation between EPTS and depressed fractures is positive (P = 0.023). Positive correlations between EPTS and intracranial hemorrhage and subarachnoid hemorrhage had been established (P = 0.011and P = 0.004, respectively). The detection rates of EPTS in the electroencephalogram (EEG) monitoring was 80.00%. There was a significant difference in the EEG monitoring rate between the two groups (P = 0.041). Forty-one (37.86%, 41/108) post-neurosurgical patients were treated with prophylactic antiepileptic drugs (AEDs), and eight (19.51%, 8/41) still had seizures. No statistical significance was noted between the two groups in terms of prophylactic AEDs use (P = 0.519). Logistic regression analysis revealed that open craniocerebral injury and fever on admission were risk factors for EPTS, whereas, surgical intervention and use of hypertonic saline were associated with not developing EPTS.Breakthrough EPTS occurred after severe TBI in 33.98% of pediatric cases in our cohort. This is a higher seizure incidence than that reported previously. Patients with fever on admission and open craniocerebral injuries are more likely to develop EPTS.© 2022. Children's Hospital, Zhejiang University School of Medicine.

Hosmann A, Schober A, Gruber A, Sterz F, Testori C, Warenits A, et al.

Cerebral and peripheral metabolism to predict successful reperfusion after cardiac arrest in rats: a microdialysis study

Neurocrit Care. 2016; 24(2):283-93.

DOI:10.1007/s12028-015-0214-x      PMID:26582187      [Cited within: 2]

In clinical practice, monitoring of the efficacy of resuscitation can be challenging. The prediction of cerebral and overall outcome in particular is an unmet medical need. Microdialysis is a minimally invasive technique for the continuous determination of metabolic parameters in vivo. Using this technique, we set out to establish a model allowing for concomitant determination of cerebral and peripheral metabolism in a cardiac arrest setting in rodents.Microdialysis settings were optimized in vitro and then used in male Sprague-Dawley rats. Probes were implanted into the CA1 region of the right hippocampus and the right femoral vein. With a time interval of 8 min, glucose, lactate, pyruvate, and glutamate levels were determined during baseline conditions, untreated ventricular fibrillation cardiac arrest, cardiopulmonary resuscitation (CPR), reperfusion, and death.In 16 rodents, restoration of spontaneous circulation was achieved in seven animals. Characteristic metabolic changes were evident during cardiac arrest and reperfusion with both probes. Ischemic patterns in peripheral compartments were delayed and more variable compared to the changes in cerebral metabolism highlighting the importance of cerebral metabolic monitoring. Microdialysis allowed distinguishing between survivors and non-survivors 8 min after termination of CPR. Cerebral glutamate showed a trend toward higher levels in non-survivors during CPR.We established a new rodent model for research in hypoxic ischemic encephalopathy. This setting allows to investigate the impact of resuscitation methods on cerebral and peripheral metabolism simultaneously. The present model may be used to evaluate different resuscitation strategies in order to optimize brain survival in future studies.

Mölström S, Nielsen TH, Nordström CH, Forsse A, Möller S, Venö S, et al.

Bedside microdialysis for detection of early brain injury after out-of-hospital cardiac arrest

Sci Rep. 2021; 11(1):15871.

DOI:10.1038/s41598-021-95405-9      PMID:34354178      [Cited within: 1]

Bedside detection and early treatment of lasting cerebral ischemia may improve outcome after out-of-hospital cardiac arrest (OHCA). This feasibility study explores the possibilities to use microdialysis (MD) for continuous monitoring of cerebral energy metabolism by analyzing the draining cerebral venous blood. Eighteen comatose patients were continuously monitored with jugular bulb and radial artery (reference) MD following resuscitation. Median time from cardiac arrest to MD was 300 min (IQR 230-390) with median monitoring time 60 h (IQR 40-81). The lactate/pyruvate ratio in cerebral venous blood was increased during the first 20 h after OHCA, and significant differences in time-averaged mean MD metabolites between jugular venous and artery measurements, were documented (p < 0.02). In patients with unfavorable outcome (72%), cerebral venous lactate and pyruvate levels remained elevated during the study period. In conclusion, the study indicates that jugular bulb microdialysis (JBM) is feasible and safe. Biochemical signs of lasting ischemia and mitochondrial dysfunction are frequent and associated with unfavorable outcome. The technique may be used in comatose OHCA patients to monitor biochemical variables reflecting ongoing brain damage and support individualized treatment early after resuscitation.© 2021. The Author(s).

Suistomaa M, Ruokonen E, Kari A, Takala J.

Time-pattern of lactate and lactate to pyruvate ratio in the first 24 hours of intensive care emergency admissions

Shock. 2000; 14(1):8-12.

PMID:10909886      [Cited within: 1]

Blood lactate elevation in critically ill patients commonly is taken as a sign of impaired tissue perfusion. Simultaneous elevation of lactate to pyruvate ratio (L/P ratio) may be helpful in discriminating between different mechanisms of hyperlactatemia and thus in determining the relevance of the finding. We studied prospectively the prevalence and the time pattern of hyperlactatemia and simultaneous L/P ratio elevation in 98 consecutive emergency admission patients in a 23-bed surgical-medical University Hospital intensive care unit. Blood lactate, L/P ratio, and blood gases were measured at 2-h intervals during the initial 24 h of intensive care unit admission. Hyperlactatemia (blood lactate over 2 mmol/L) was found in 48 (49%) patients, and the median peak value of the non-survivors was higher than that of the survivors [5.3 (interquartile range 1.9-7.5) vs. 1.9 (1.3-2.9) mmol/L, respectively, p = 0.003]. Hyperlactatemia at admission (n = 31) was associated with a higher hospital mortality than hyperlactatemia developing later (n = 17) (29.0% vs. 5.9%, P = 0.003). Sustained admission hyperlactatemia (>6 h) was associated with higher mortality than short-lasting hyperlactatemia (36.8% vs. 0%, P = 0.008). Simultaneously elevated L/P ratio (L/P ratio > 18; n = 16) was associated with higher mortality than hyperlactatemia with normal L/P ratio (n = 32; 37.5% vs. 12.5%, respectively, P = 0.03) and was found mainly in patients who had severe circulatory failure. The hyperlactatemia of patients with sepsis was not associated with L/P ratio elevation. We conclude that hyperlactatemia is common in emergency admission patients. Hyperlactatemia with L/P ratio elevation and lactic acidosis is likely to be associated with inadequate tissue perfusion. Hyperlactatemia persisting more than 6 h and simultaneous elevation of L/P ratio are associated with increased mortality.

Jha MK, Lee IK, Suk K.

Metabolic reprogramming by the pyruvate dehydrogenase kinase-lactic acid axis: linking metabolism and diverse neuropathophysiologies

Neurosci Biobehav Rev. 2016; 68:1-19.

DOI:S0149-7634(16)30102-6      PMID:27179453      [Cited within: 1]

Emerging evidence indicates that there is a complex interplay between metabolism and chronic disorders in the nervous system. In particular, the pyruvate dehydrogenase (PDH) kinase (PDK)-lactic acid axis is a critical link that connects metabolic reprogramming and the pathophysiology of neurological disorders. PDKs, via regulation of PDH complex activity, orchestrate the conversion of pyruvate either aerobically to acetyl-CoA, or anaerobically to lactate. The kinases are also involved in neurometabolic dysregulation under pathological conditions. Lactate, an energy substrate for neurons, is also a recently acknowledged signaling molecule involved in neuronal plasticity, neuron-glia interactions, neuroimmune communication, and nociception. More recently, the PDK-lactic acid axis has been recognized to modulate neuronal and glial phenotypes and activities, contributing to the pathophysiologies of diverse neurological disorders. This review covers the recent advances that implicate the PDK-lactic acid axis as a novel linker of metabolism and diverse neuropathophysiologies. We finally explore the possibilities of employing the PDK-lactic acid axis and its downstream mediators as putative future therapeutic strategies aimed at prevention or treatment of neurological disorders.Copyright © 2016 Elsevier Ltd. All rights reserved.

Fukuda T, Ohashi-Fukuda N, Sekiguchi H, Inokuchi R, Kukita I.

Survival from pediatric out-of-hospital cardiac arrest during nights and weekends: an updated japanese registry-based study

JACC Asia. 2022; 2(4):433-43.

[Cited within: 1]

Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al.

Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis

Am J Emerg Med. 2020; 38(9):1722-6.

DOI:S0735-6757(20)30436-8      PMID:32738466      [Cited within: 1]

Coronavirus disease 2019 (COVID-19) infection has now reached a pandemic state, affecting more than a million patients worldwide. Predictors of disease outcomes in these patients need to be urgently assessed to decrease morbidity and societal burden. Lactate dehydrogenase (LDH) has been associated with worse outcomes in patients with viral infections. In this pooled analysis of 9 published studies (n = 1532 COVID-19 patients), we evaluated the association between elevated LDH levels measured at earliest time point in hospitalization and disease outcomes in patients with COVID-19. Elevated LDH levels were associated with a ~6-fold increase in odds of developing severe disease and a ~16-fold increase in odds of mortality in patients with COVID-19. Larger studies are needed to confirm these findings.Copyright © 2020 Elsevier Inc. All rights reserved.

Khalilov RA, Dzhafarova AM, Khizrieva SI.

Effect of hypothermia on kinetic characteristics of lactate dehydrogenase in rat brain under conditions of global ischemia and reperfusion

Bull Exp Biol Med. 2017; 163(3):334-7.

[Cited within: 1]

/